Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07003100 · ClinicalTrials.gov registry record
A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab
A clinical trial of Recurrent Mycosis Fungoides and Refractory Mycosis Fungoides, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- 100
- Enrollment target
- 10
- Study locations
NCT07003100: Recruiting study of Recurrent Mycosis Fungoides and Refractory Mycosis Fungoides, sponsored by City of Hope Medical Center.
NCT07003100 is a study of Recurrent Mycosis Fungoides and Refractory Mycosis Fungoides that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 100 participants, above the 50-participant average among 6 other Recurrent Mycosis Fungoides trials with a reported enrollment target (100% higher). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07003100, a study of Recurrent Mycosis Fungoides and Refractory Mycosis Fungoides, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study is being done to assess mogamulizumab-associated rash in patients diagnosed with mycosis fungoides or sezary syndrome and treated with standard of care mogamulizumab. One of the most common side effects of mogamulizumab is a rash, currently named mogamulizumab-associated rash (MAR) which can look like MF or SS. However, mogamulizumab-associated rash (MAR) does not indicate failure of mogamulizumab, and may be a sign that the drug is working. If not properly evaluated, mogamulizumab-associated rash (MAR) could be misinterpreted as worsening of mycosis fungoides/sezary syndrome, which could lead doctors to recommend stopping mogamulizumab treatment early. The information learned by doing this research study may help tell the difference between mogamulizumab-associated rash (MAR) (sometimes also called "drug eruption") and worsening of the disease. It may also help to uncover information about the cause of mogamulizumab-associated rash (MAR).
Primary Outcome
Will be estimated as a binomial proportion along with the 95% exact binomial confidence interval.
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (10)
California
- City of Hope Medical Center - Duarte
- Stanford Cancer Institute Palo Alto - Palo Alto
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
Massachusetts
- Brigham and Women's Hospital - Boston
Missouri
- Siteman Cancer Center at Washington University - St Louis
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-12-06 |
| Est. Completion | 2026-10-19 |
What NCT07003100 shows while recruiting
NCT07003100 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 50-participant average among 6 other Recurrent Mycosis Fungoides trials with a reported enrollment target (100% higher).
The record links to 9 conditions, with Recurrent Mycosis Fungoides appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT07003100 lists 10 locations in 9 states (California, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT07003100 about?
NCT07003100 is a clinical study titled "A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab". This study is being done to assess mogamulizumab-associated rash in patients diagnosed with mycosis fungoides or sezary syndrome and treated with standard of care mogamulizumab. One of the most common side effects of mogamulizumab is a rash, currently named mogamulizumab-associated rash (MAR) which ...
What is the current status of trial NCT07003100?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2024-12-06. Estimated completion is 2026-10-19.
What conditions does trial NCT07003100 study?
This clinical trial studies the following conditions: Recurrent Mycosis Fungoides, Refractory Mycosis Fungoides, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8.
What interventions are being tested in trial NCT07003100?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT07003100?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07003100 being conducted?
This trial has 10 study locations across California, Florida, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Mycosis Fungoides
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
RECRUITING · Phase 1
-
Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides
RECRUITING
-
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
ACTIVE NOT RECRUITING · Phase 1
-
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
ACTIVE NOT RECRUITING · Phase 1
-
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI